Establishment Labs: Analysts bullish on potential of new breast implant

Establishment Labs Holdings

15/12/2020 13:26

** Medical technology co Establishment Labs Holdings Inc
 ESTA.O  said on Monday it received CE mark for its next
generation Ergonomix2 silicone breast implant, certifying
conformity to European standards 
    ** Co plans to introduce E2 implant to Europe in H1 2021
 urn:newsml:reuters.com:*:nGNX1LJB3K
    ** Co said CE mark also includes its "Diamond" breast
implant, that will be used in its Motiva Mia minimally-invasive
breast augmentation system when approved
    ** Jefferies says more anatomical shape offered by E2
implant could appeal to surgeons still using textured devices
despite concerns surrounding higher risks
    ** BTIG views breast implant as "disruptive technology"
which could replace current implants; raises PT to $41 from $33
    ** Cites implant's "unique appearance, natural feel and
impressive safety profile" as positives in breast implant
industry which has "experienced relatively minimal design
innovation and discouraging adverse event rates over many years"
    ** Cowen thinks Mia system can attract patients who would
not have previously considered having an augmentation procedure,
thus potentially expanding breast augmentation market 
    ** Avg rating on stock is "buy"; Median PT is $35
    ** Up to Monday's close, ESTA had risen 13.9% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))